Johnson & Johnson: 3 Key Takeaways for Long-Term Investors
MedTech growth stalled while pharma surged, leaving the company to bet on new product launches and a planned spin-off to restore momentum.
Three key takeaways emerged from Johnson & Johnson's third quarter 2026 earnings call on October 13, 2026.
Firstly, the Innovative Medicine division led growth, with a 7.9% increase in operational performance. This segment, which focuses on developing prescription drugs, saw significant gains, with cancer treatments playing a major role and Tremfya, a therapy for inflammatory diseases, expanding market share.
Secondly, while MedTech (the medical device segment) experienced slower growth at 2.5%, this was due to various challenges including disruptions in the Middle East, procurement issues, Chinese government buying programs, and delays in adopting Abiomed heart pumps. Management is optimistic about restoring double-digit growth through new product rollouts, like their soft-tissue robotic surgery system OTTAVA.
Lastly, the company's strategy involves internal investments rather than large acquisitions to achieve double-digit growth. Management is considering a tax-free spinoff of DePuy Synthes, their orthopedics subsidiary, by mid-2027, which they believe will create long-term value for shareholders. They remain confident about finishing 2026 strong and expect even better results in 2027.
Written by urgent.news from Motley Fool's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
